Pfizer says its Covid-19 vaccine 100% effective on 12 to 15-year-olds
PTI, Mar 31, 2021, 5:05 PM IST
New Delhi: BioNTech-Pfizer said Wednesday their vaccine showed 100 per cent efficacy against the coronavirus in 12 to 15-year-olds, as they eye approval for adolescents to get the jabs before the next school year.
Phase 3 trials carried out on 2,260 adolescents in the United States “demonstrated 100 per cent efficacy and robust antibody responses”, the companies said in a statement.
“We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year,” said Pfizer chief executive Albert Bourla.
Chief executive of German company BioNTech said the results showing high protection for teens were “very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant”.
The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 vaccine to be approved in the West late last year.
Both the United States and the European Union have approved its use for people aged 16 and above.
Since then, it has been used in millions of adults in more than 65 countries.
A real world study involving 1.2 million people in Israel found it to be 94 per cent effective.
With the world scrambling to inoculate, BioNTech said Tuesday it was on track to manufacture 2.5 billion doses of its vaccine this year.
The higher output was driven by the recent launch of a new production site in the German city of Marburg, which is now one of the world’s largest mRNA vaccine manufacturing plants, it said.
The vaccine is also being produced at a Pfizer plant in Belgium and at three sites in the United States.
BioNTech said improved efficiency and new cooperation agreements with outside partners had also helped lift its vaccine target, as had the regulatory nod allowing vaccinators to extract six instead of just five doses from a single BioNTech/Pfizer vial.
BioNTech and Pfizer last week began studies of the jab on children, with the first group of 5 to 11-year-olds getting the vaccine.
A younger cohort of 2 to 5-year-olds are expected to get their first dose next week in the study which will also cover children as young as six months old.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
BTS2024: If India can make rocket sensors, it can also make car sensors, says ISRO chief Somanath
World COPD Day: Know your lung function
SpaceX successfully launches ISRO’s 4,700 kg communication satellite from US
As AI and megaplatforms take over, the hyperlinks that built the web may face extinction
Plastic waste could double by 2050, researchers find, suggest policies to address issue
MUST WATCH
Latest Additions
Mangaluru: Cyber frauds posing as TRAI representatives fleece Rs 1.71 crore
10 month baby gets new heart, new life
Saura Swasthya launched: Karnataka to power 5,000 health facilities with solar energy
India-US ties have strong foundation: White House confident in navigating crisis over Adani bribery charges
PM Modi leaves for home after concluding three-nation visit
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.